More than two million seniors and people with disabilities (SPDs) enrolled in Medi-Cal in California will be impacted by reforms, initiatives, and new policies being developed through CalAIM (California Advancing and Innovating Medi-Cal).

CalAIM (California Advancing and Innovating Medi-Cal) is a comprehensive, multiyear effort led by the California Department of Health Care Services that seeks to implement broad delivery system, program, and payment reform across California’s Medi-Cal program.

At this crucial moment before a second wave of COVID-19 crests and crashes, policymakers should confront a significant payment problem brewing within our primary-care safety net that, if unaddressed, threatens care for millions of Americans.

In communities across the country, staggering unemployment rates and failing infrastructure go hand in hand with significant healthcare challenge

The need to bring high-quality treatment and management of depression, anxiety, and other common behavioral health conditions into primary care has been well documented, but for small to medium-size practices the complex models that are the standard for integrating medical and behavioral care are often beyond their resources.

This chapter traces the history of Montefiore’s Accountable Care Organization (ACO) development including care management experience prior to the Affordable Care Act, administrative structure, and the use of care management as a central element in its ACO.

The Affordable Care Act hastened the emergence of a new healthcare delivery and payment model called Accountable Care Organizations (ACOs).

This report offers an evaluation of Merck-Wellcome Trust Hilleman [...]

The discussion focuses on two victims’ rights: notification and information concerning the location and case status of defendants and those convicted of the crimes at issue for victims; and participation in hearings and court proceedings related to the case.

When Will Cross, a diabetic, attempted to scale Mount Everest this May, Novo Nordisk not only helped sustain his life with its insulin drug, NovoLog. The Princeton, N.J., pharmaceutical company also footed the $60,000-plus bill for the climb.